Alzamend Neuro (NASDAQ:ALZN) Releases Earnings Results, Beats Estimates By $0.10 EPS

Alzamend Neuro (NASDAQ:ALZN) posted its quarterly earnings data on Monday. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.10, Zacks reports.

Alzamend Neuro Price Performance

Shares of NASDAQ:ALZN opened at $0.70 on Wednesday. Alzamend Neuro has a 1-year low of $0.66 and a 1-year high of $15.06. The business’s 50 day moving average is $1.05 and its 200-day moving average is $1.40.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets reduced their price target on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a report on Monday, December 16th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.